Concurrent tamoxifen (TAM) + cyclophosphamide, epirubicin, and fluorouracil (CEF) versus TAM + delayed CEF after six months of endocrine therapy in metastatic breast cancer--a randomized trial from the Danish Breast Cancer Cooperative Group (DBCG).
about
Concurrent tamoxifen (TAM) + cyclophosphamide, epirubicin, and fluorouracil (CEF) versus TAM + delayed CEF after six months of endocrine therapy in metastatic breast cancer--a randomized trial from the Danish Breast Cancer Cooperative Group (DBCG).
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Concurrent tamoxifen (TAM) + c ...... ncer Cooperative Group (DBCG).
@en
Concurrent tamoxifen (TAM) + c ...... ncer Cooperative Group (DBCG).
@nl
type
label
Concurrent tamoxifen (TAM) + c ...... ncer Cooperative Group (DBCG).
@en
Concurrent tamoxifen (TAM) + c ...... ncer Cooperative Group (DBCG).
@nl
prefLabel
Concurrent tamoxifen (TAM) + c ...... ncer Cooperative Group (DBCG).
@en
Concurrent tamoxifen (TAM) + c ...... ncer Cooperative Group (DBCG).
@nl
P2093
P2860
P1433
P1476
Concurrent tamoxifen (TAM) + c ...... ncer Cooperative Group (DBCG).
@en
P2093
Andersson M
Ejlertsen B
Mouridsen HT
Pedersen D
Pfeiffer P
P2860
P356
10.3109/02841869609083988
P478
35 Suppl 5
P577
1996-01-01T00:00:00Z